Cancer Genetics and Epigenetics, 2025, Vol.13, No.3, 126-135 http://medscipublisher.com/index.php/cge 132 condition does not deteriorate is also shorter. It seems that MAGEA3 causes tumors to develop drug resistance by affecting the mTOR pathway, reducing the production of VEGF, and also disrupting the function of mitochondria in cells. This provides a promising direction for classifying and treating patients by finding indicators in the future (Wang et al., 2025). 7.2 Exploration of new strategies such as combined immunotherapy As people's understanding of the role of bevacizumab in altering the environment around tumors increases, new combination treatment methods have begun to be attempted, especially when used in combination with immunotherapy. Bevacizumab can not only prevent tumors from growing new blood vessels, but also reduce the suppression of the human immune system by tumors. This may make the therapeutic effect of immune checkpoint inhibitors better (Coleman et al., 2020; Verma et al., 2025). Currently, some clinical trials are underway to study the combination of bevacizumab with atazolizumab and all-trans retinoic acid, hoping to solve the problem of drug resistance in microsatellite stable colorectal cancer by altering the environment around the tumor and reducing those cells that suppress the immune system. These new treatment methods may enable bevacizumab to treat more types of cancers than it does now (Coleman et al., 2020; Verma et al., 2025). 7.3 The development potential of personalized and precise treatment models Treating patients based on their individual conditions to achieve precision medicine has become an important direction in the research of treating metastatic colorectal cancer. The advancements in genetic research and molecular detection technologies have led people to strive to formulate bevacizumab treatment plans suitable for each patient based on their characteristics, such as whether there are gene mutations, the nature of the tumor, and the reasons for drug resistance (Yeung and Tebbutt, 2012; Coleman et al., 2020; Lei et al., 2025). The ongoing research currently focuses on integrating the search for indicators, the trial of new drug combinations, and the data from actual treatments. This way, it is possible to better select patients suitable for medication and achieve better treatment outcomes. The development of biosimilars and the improvement of targeted therapy technologies have also made it more possible to achieve more personalized and effective treatment models in the future (Burkes et al., 2017; Coleman et al., 2020; Lei et al., 2025). 8 Concluding Remarks When treating advanced or metastatic colorectal cancer, adding bevacizumab to the commonly used chemotherapy regimens can significantly prolong the time for patients' conditions to not deteriorate and the overall survival time. Many comprehensive analyses and large-scale comparative trials have found that compared with chemotherapy alone, after adding bevacizumab, patients' conditions do not deteriorate and their survival time is longer, which indicates that treatment with it can enable patients to live better. Whether it is at the beginning of treatment or later treatment, this treatment method is effective. Even for those difficult-to-treat cases, using it together is also useful. Therefore, bevacizumab is an important drug for the treatment of advanced colorectal cancer. The side effects brought by bevacizumab can generally be controlled. The most common side effects include elevated blood pressure, protein in urine, bleeding and vascular blockage. Most of the side effects are not serious, but rare but dangerous conditions such as intestinal perforation and poor wound healing may also occur. Therefore, patients need to be carefully observed during treatment. Although the probability of serious side effects is not high, doctors must be cautious, especially for those patients who already have other risk factors. Once a problem is detected, it should be dealt with promptly. Although bevacizumab is indeed effective in treating colorectal cancer, there are still many difficulties in using this drug well. Now there is an urgent need to find reliable methods to know in advance which patients have the best effect after taking the medicine and which patients are more likely to have side effects. Future research should focus on how to treat patients according to their individual conditions, try new combined treatment
RkJQdWJsaXNoZXIy MjQ4ODYzNA==